All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Interfant-06 study: Why should we assess end-of-consolidation MRD in infants with ALL?
Bookmark this article
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Janine Stutterheim, Princess Máxima Center, Utrecht, NL. We asked, Why should we assess end-of-consolidation measurable residual disease (MRD) in infants with ALL?
Interfant-06 study: Why should we assess end-of-consolidation MRD in infants with ALL?
In this podcast, Stutterheim discusses the prognostic value of MRD for survival outcomes at the end of consolidation in infants with ALL. She also discusses the predictive value of MRD status at the end of induction of therapy for selecting different consolidation therapies. Finally, she reports the relationship of MRD status at the end of induction with myeloid markers in the context of selecting myeloid-style therapy.
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox